AbbVie Inc

• Eli Lilly outperformed broader markets as investors rotated into resilient healthcare leaders. • Analysts upgraded earnings expectations due to strong demand for metabolic drugs. • Technical indicators show a buy signal with an extremely bullish market sentiment.

• AbbVie presented Phase 3 AFFIRM study data for Skyrizi in Crohn's disease. • The company reported an annual revenue of $61.16B and net profit of $4.19B. • Analysts assigned Buy ratings with an average price target of $281.30.

• Johnson & Johnson reported Q3 revenue beats but missed adjusted earnings expectations. • MedTech international sales and oncology revenues faced geopolitical and pricing headwinds. • The stock exhibits a MACD sell signal alongside an oversold Williams %R.

• Tempus AI experienced strong buying momentum and pronounced intraday price volatility. • CEO Eric Lefkofsky presented a compelling revenue growth outlook at conference. • The company reported an annual revenue of $1.27B and net profit of $-245.03M.

• Arrowhead shares dropped despite positive Phase 1/2a data for ARO-DIMER-PA due to profit-taking. • The company reported annual revenue of $829.45M with a net loss of $1.63M. • Technical indicators show a MACD sell signal and an RSI of 27.985.

• Ascendis Pharma stock fell after terminating its collaboration agreement with Novo Nordisk. • Investors worry about independent funding and high expenses for obesity clinical programs. • The company reported an annual revenue of $854.80M and net loss.